Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug (Azacitidine, Lenalidomide, Decitabine, Deferasirox), and Geography - Insights, Size, Share, Opportunity Analysis, & Industry Forecast till 2025

According to the American Society of Hematology, in 2016, prevalence of MDS ranged from 0.22-13.2 per 100,000, on all age categories and ethnicities globally. Increasing public awareness about the disease and introduction of new treatment for MDS will drive the growth of the market. Furthermore, growing aging population is analyzed to be a major factor propelling the growth of myelodysplastic syndrome treatment market. According to NCBI, 2012, the incidence of MDS increases significantly with age and the disease is most prevalent in males. Besides, companies such as Celgene and Novartis, who offer innovative brands in this market would be able to combat the loss of share, post patent expiry through their pipeline molecules expected to be launched during the forecast period.

This report segments the global myelodysplastic syndrome treatment market on the basis of drugs. On the basis of drugs, the global Myelodysplastic syndrome treatment market is classified into Azacitidine, Lenalidomide, Decitabine, and Deferasirox. For comprehensive understanding of market dynamics, the global myelodysplastic syndrome treatment market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/775

The genetic transformations associated with the disease and biologics of the MDS is being explored. Diagnosis and treatment options are being researched at various standard cancer research centers. Mutations of TP53, TET2, and DNMT3A have been identified as possible MDS patients with shorter OS after allogenic HSCT which suggests the need of alternative treatment options than transplantation.

Extensive research studies are being performed on existing treatment options such as chemotherapy, immune suppression, targeted therapy, stem cell transplant, and drugs to raise platelet counts such as Romiplostim (Nplate), which is used as a therapy for a disease called as Immune thrombocytopenic purpura (ITP). However, recent studies reports to have increased platelet counts in people with MDS according to the American Cancer Society.

Awareness initiatives to lead to early diagnosis and treatment

Furthermore, governmental organizations and drug manufacturing companies are spreading awareness about the disease with various ways, such as by providing funding and conducting awareness programs. MDS International Foundation is one such organization which is supporting the patients through various ways be it treatment or psychological support. Furthermore EvansMDS a funding initiative of the Edward P.Evans Foundation has awarded $45 Mn since 2011 for research specifically focused on MDS and AML.

Key players operating in the myelodysplastic syndrome treatment market include Celgene, Novartis, and Otsuka. Some of the other market players are Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline, Eli-Lilly, and CTI Biopharma.

Complete Report Details @ https://www.coherentmarketinsights.com/press-release/increase-in-diagnosis-rate-is-expected-to-surge-the-myelodysplastic-syndrome-treatment-market-to-us-57-bn-2025-343

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.